This study will examine how Jublia affects dermatophytomas, which are difficult to treat with other therapeutic options.
Dermatophytomas are known to be resistant to even long courses of systemic antifungals, and have therefore been excluded from both topical and systemic clinical trials for onychomycosis, including those for Efinaconazole solution. Efinaconazole (Jublia) 10% solution is an FDA approved topical medication indicated for treatment of distal lateral subungual onychomycosis (DLSO), and the utility of this medication likely exceeds published results. Efinaconazole solution's novel ability to penetrate into the subungual space likely accounts for improved treatment results seen in DLSO treated with Jublia. We will investigate the utility of topical efinaconazole solution in the treatment of dermatophytomas.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
19
Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.
The Kirklin Clinic
Birmingham, Alabama, United States
Number of Participants With Elimination of Dermatophytomas That Occur in Distal Lateral Subungual Onychomycosis (DLSO)
Clear nail growth between the proximal nail fold and the dermatophytoma's proximal edge will be measured.
Time frame: week 48
Clinical or Mycological Cure of Nail
Completely normal nail plate or negative fungal culture
Time frame: week 48
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.